| Literature DB >> 23506136 |
Marlies E van Wolfswinkel1, Klaske Vliegenthart-Jongbloed, Mariana de Mendonça Melo, Peter C Wever, Matthew B McCall, Rob Koelewijn, Jaap J van Hellemond, Perry J van Genderen.
Abstract
BACKGROUND: Lymphocytopenia has frequently been described in patients with malaria, but studies on its association with disease severity have yielded conflicting results. The neutrophil/lymphocyte count ratio (NLCR) has been introduced as a parameter for systemic inflammation in critically ill patients and was found, together with lymphocytopenia, to be a better predictor of bacteraemia than routine parameters like C-reactive protein and total leukocyte count. In the present study, the predictive value of the NLCR and lymphocytopenia for severe disease was evaluated in patients with imported malaria.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23506136 PMCID: PMC3608093 DOI: 10.1186/1475-2875-12-101
Source DB: PubMed Journal: Malar J ISSN: 1475-2875 Impact factor: 2.979
General characteristics
| | ||||
|---|---|---|---|---|
| | | | | |
| Age, years | 44 (4–70) | 39 (11–78) | 36 (15–77) | 0.0005* |
| Male/female, n (%) | 39 (64%)/ 22 (36%) | 191 (74%) / 68 (26%) | 83 (69%)/37 (31%) | NS# |
| | | | 0.0029# | |
| | 42 (69%) | 123 (47%) | N/A | |
| | 19 (31%) | 118 (46%) | N/A | |
| | 0 (0%) | 3 (1%) | N/A | |
| | 0 (0%) | 16 (6%) | N/A | |
| | | | NS# | |
| Africa, n (%) | 56 (92%) | 240 (93%) | 42 (35%) | |
| Asia, n (%) | 3 (5%) | 11 (4%) | 50 (42%) | |
| South and Central America, n (%) | 1 (2%) | 5 (2%) | 26 (22%) | |
| Unknown, n (%) | 1 (2%) | 3 (1%) | 2 (2%) | |
| | | | 0.007# | |
| <8 days, n (%) | 38 (62%) | 177 (68%) | 58 (48%) | |
| 8-14 days, n (%) | 17 (28%) | 45 (17%) | 24 (20%) | |
| 15-28 days, n (%) | 2 (3%) | 20 (8%) | 11 (9%) | |
| >28 days, n (%) | 0 (0%) | 5 (2%) | 8 (7%) | |
| Unknown, n (%) | 4 (7%) | 12 (5%) | 19 (16%) | |
| | | | <0.0001# | |
| No chemoprophylaxis, n (%) | 49 (80%) | 182 (70%) | 51 (43%) | |
| Inadequate use, n (%) | 8 (13%) | 46 (18%) | 15 (13%) | |
| Adequate use, n (%) | 2 (3%) | 20 (8%) | 42 (35%) | |
| Unknown, n (%) | 2 (3%) | 11 (4%) | 12 (10%) | |
| | | | | |
| Body temperature, °C | 38.4 (35.7-41.2) | 38.5 (35.5-41.0) | 38.9 (36.0-41.2) | NS* |
| Pulse rate, beats per minute | 103 (50–150) | 90 (45–140) | 90 (58–138) | 0.0005* |
| Systolic blood pressure, mm Hg | 117 (80–160) | 120 (73–185) | 120 (90–196) | N.T. |
| Impaired consciousness (GCS<15), n (%) | 8 (13%) | 1 (0%) | 0 (0%) | N.T. |
| Coma (GCS≤11), n (%) | 3 (5%) | 0 (0%) | 0 (0%) | N.T. |
| | | | | |
| Haemoglobin, mmol/L | 7.8 (2.5-10.9) | 8.4 (4.0-11.1) | 8.2 (4.6-11.2) | N.T. |
| Thrombocytes, × 109/L | 39 (3–188) | 101 (18–293) | 95 (10–292) | <0.0001* |
| C-reactive protein, mg/L | 182 (65–476) | 85 (5–320) | 71 (14–348) | <0.0001* |
| Serum creatinine, μmol/L | 114 (39–1081) | 93 (47–238) | 90 (53–255) | N.T. |
| Serum sodium, mmol/L | 131 (115–146) | 135 (119–145) | 135 (124–148) | <0.0001* |
| Lactate dehydrogenase, U/L | 485 (139–2038) | 268 (118–947) | 246 (127–775) | <0.0001* |
| Total bilirubin, μmol/L | 53 (13–416) | 22 (4–164) | 22 (3–99) | N.T. |
| Plasma lactate, mmol/L | 2.3 (0.6-6.2) | 1.4 (0.5-4.6) | 1.3 (0.6-4.0) | <0.0001* |
| | | | | |
| Total leukocyte count, × 109/L | 6.9 (2.5-18.5) | 4.9 (1.3-13.4) | 5.3 (1.9-15.3) | <0.0001* |
| Neutrophil count, × 109/L | 3.6 (0.6-10.4) | 3.1 (0.4-11.0) | 3.2 (1.0-11.6) | 0.0064* |
| Neutrophil count% | 60 (19–85) | 64 (13–91) | 64 (20–88) | NS* |
| Lymphocyte count, × 109/L | 1.0 (0.2-4.2) | 0.9 (0.1-5.0) | 1.1 (0.3-6.1) | NS* |
| Lymphocyte count % | 15 (4–45) | 19 (2–74) | 21 (5–74) | 0.0036* |
| NLCR | 3.5 (0.7-17.0) | 3.3 (0.2-46) | 2.8 (0.3-17.6) | NS* |
| | | | | |
| | 230,000 (520–1,380,600) | 4,288 (2–208,000) | N/A | N.T. |
| Presence of | 33 (54%) | 11 (4%) | N/A | <0.0001^ |
| | | | | |
| All concomitant infections | 8 (13%) | 11 (4%) | 10 (8%) | <0.0001# |
| Concomitant bacterial infection | 5 (8%) | 3 (1%) | 2 (2%) | 0.004# |
* Comparison of 3 groups using the Kruskal Wallis test, # Comparison of 3 groups using the Chi-Square Test, ^ Comparison of 2 groups using Fisher’s Exact test. Parameters that are included in the modified WHO severity criteria for severe falciparum malaria were not tested (N.T.).
Figure 1Distribution of leukocyte counts and the NLCR in patients with malaria grouped by severity and causative Plasmodium species.
Descriptive statistics of diagnostic performance for severe malaria
| ≥ | 0.59 (0.46-0.71) | 0.75 (0.71-0.80) | 0.28 (0.21-0.37) | 0.92 (0.88-0.95) | 0.34 | 0.70 (0.63-0.78) | |
| ≥ | 0.64 (0.51-0.76) | 0.56 (0.51-0.61) | 0.19 (0.14-0.25) | 0.91 (0.86-0.94) | 0.2 | 0.61 (0.53-0.69) | |
| 0.33 (0.22-0.46) | 0.72 (0.67-0.76) | 0.16 (0.10-0.24) | 0.87 (0.83-0.90) | 0.05 | 0.51 (0.43-0.59) | ||
| ≥ | 0.77 (0.64-0.86) | 0.44 (0.39-0.49) | 0.18 (0.14-0.24) | 0.92 (0.87-0.96) | 0.21 | 0.57 (0.50-0.64) | |
| 0.80 (0.67-0.89) | 0.76 (0.71-0.80) | 0.33 (0.25-0.42) | 0.96 (0.93-0.98) | 0.56 | 0.84 (0.79-0.89) |
Leukocyte count changes during malaria treatment
| | | | | |
| CRP, mg/L | 184 (108–373) | 49 (1–206) | 29 | <0.0001 |
| Total leukocyte count, x 109/L | 6.8 (2.5-18.5) | 7.8 (3.1-16.4) | 40 | 0.0045 |
| Neutrophil count, x 109/L | 3.5 (1.2-10.4) | 4.0 (1.4-10.7) | 40 | NS |
| Lymphocyte count, x 109/L | 0.9 (0.2-4.2) | 2.1 (0.2-5.8) | 40 | <0.0001 |
| NLCR | 4.0 (0.9-17.0) | 2.1 (0.5-20.3) | 40 | 0.0011 |
| | | | | |
| CRP, mg/L | 96 (5–284) | 14 (1–250) | 116 | <0.0001 |
| Total leukocyte count, x 109/L | 4.8 (1.3-13.4) | 5.6 (2.2-16.9) | 161 | <0.0001 |
| Neutrophil count, x 109/L | 3.0 (0.6-8.8) | 2.5 (0.3-11.9) | 114 | 0.0075 |
| Lymphocyte count, x 109/L | 0.9 (0.2-3.1) | 2.0 (0.3-4.5) | 114 | <0.0001 |
| NLCR | 3.3 (0.5-19.0) | 1.3 (0.3-11.0) | 114 | <0.0001 |